Akums Drugs And Pharmaceuticals Peer Comparison
NSE: AKUMS | BSE: 544222
₹765.85
₹22.05
(2.96%)
As on 09-Nov-2026IST
Market cap
₹12,046 Cr
Revenue (TTM)
₹4,826 Cr
P/E Ratio
33.1
P/B Ratio
3.4
Div. Yield
0.4 %
Edit
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
12,046 | 32,864 | 33,015 | 31,746 | 29,317 |
Revenue (₹ Cr) |
4,826 | 9,779 | 3,751 | 1,593 | 2,100 |
Net Profit (₹ Cr) |
364.56 | -270.51 | 405.00 | 438.64 | 324.79 |
Net Margin (%) |
7.36 | -2.71 | 10.48 | 27.16 | 15.36 |
RoE (%) |
11.07 | -2.55 | 7.91 | 25.02 | 24.02 |
Price to Earnings |
33.11 | -- | 80.52 | 72.29 | 90.25 |
Price-To-Book |
3.44 | 4.03 | 6.40 | 17.09 | 20.70 |
Income Statement (₹ Cr)
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4,826.47 | 9,778.62 | 3,751.00 | 1,592.52 | 2,100.17 |
|
Total Income
|
4,955.39 | 9,993.26 | 3,863.00 | 1,615.23 | 2,114.53 |
|
Total Expenditure
|
4,158.49 | 8,578.44 | 2,984.00 | 969.32 | 1,600.14 |
|
EBITDA
|
667.98 | 1,200.18 | 767.00 | 623.20 | 500.03 |
|
Depreciation
|
164.04 | 887.82 | 228.00 | 41.96 | 57.00 |
|
EBIT
|
503.94 | 312.36 | 539.00 | 581.24 | 443.03 |
|
Interest
|
98.07 | 347.94 | 218.00 | 4.21 | 40.83 |
|
Other Income
|
128.92 | 214.64 | 112.00 | 22.71 | 14.37 |
|
Exceptional Items
|
-20.02 | -216.88 | 12.00 | 0.00 | 0.00 |
|
Profit before Tax
|
514.76 | -37.82 | 445.00 | 599.74 | 416.57 |
|
Provision for Tax
|
150.20 | 232.69 | 40.00 | 161.10 | 91.78 |
|
Profit after Tax
|
364.56 | -270.51 | 405.00 | 438.64 | 324.79 |
Liabilities (₹ Cr)
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
3,502.87 | 8,142.24 | 5,158.00 | 1,857.45 | 1,416.33 |
|
Minority Interest
|
-0.77 | 0.55 | 5.00 | 0.51 | 0.05 |
|
Non-Current Liabilities
|
1,042.70 | 5,213.99 | 1,617.00 | 47.15 | 376.76 |
|
Current Liabilities
|
1,265.58 | 5,158.51 | 1,785.00 | 253.37 | 952.98 |
|
Total Liabilities
|
5,429.26 | 17,723.32 | 8,578.00 | 1,983.96 | 2,326.71 |
Assets (₹ Cr)
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,726.87 | 10,687.30 | 5,527.00 | 1,132.12 | 798.30 |
|
Current Assets
|
3,825.88 | 7,253.65 | 2,764.00 | 1,012.00 | 1,747.21 |
|
Total Assets
|
5,429.26 | 17,723.32 | 8,578.00 | 1,983.96 | 2,326.71 |
|
Total Debt*
|
72.95 | 5,495.48 | 2,125.00 | 26.49 | 259.37 |
|
Net Current Assets
|
2,560.30 | 2,095.14 | 979.00 | 758.64 | 794.23 |
|
Contingent Liabilities
|
99.40 | 95.72 | 768.26 | 17.25 | 19.09 |
Cashflow (₹ Cr)
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,181.20 | 1,652.60 | 390.00 | 292.17 | 205.05 |
|
Cash Flow from Investing Activities
|
-930.27 | -826.03 | -241.00 | -265.94 | -409.72 |
|
Cash from Financing Activities
|
33.88 | -38.98 | -54.00 | 4.10 | 283.07 |
|
Net Cash Inflow / Outflow
|
284.81 | 787.59 | 95.00 | 30.33 | 78.39 |
Ratios
Profitability Ratios
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
ROCE (%)
|
14.77 | 1.24 | 6.79 | 32.42 | 29.22 |
|
ROE (%)
|
11.07 | -2.55 | 7.91 | 25.02 | 24.02 |
|
ROA (%)
|
6.63 | -1.56 | 4.65 | 22.40 | 14.30 |
|
EBIT Margin (%)
|
10.44 | 3.19 | 14.37 | 36.50 | 21.09 |
|
Net Margin (%)
|
7.36 | -2.71 | 10.48 | 27.16 | 15.36 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
17.50 | 9.43 | 25.70 | 45.18 | 46.25 |
|
EBIT Growth (%)
|
80.35 | -3.72 | 139.56 | 115.51 | 60.95 |
|
Net Profit Growth (%)
|
12.76 | -199.34 | 894.12 | 95.80 | 89.41 |
|
EPS Growth (%)
|
26.79 | -410.28 | 599.72 | 63.29 | 76.32 |
|
Book Value Growth (%)
|
8.74 | 0.33 | 13.47 | 26.03 | 144.31 |
Valuation Ratios
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Price / Earnings
|
31.94 | -158.04 | 82.63 | 72.29 | 90.07 |
|
Price / Book Value
|
3.44 | 4.03 | 6.40 | 17.09 | 20.70 |
|
Dividend Yield (%)
|
0.39 | 0.00 | 0.00 | 0.06 | 0.08 |
|
EV/EBITDA
|
15.63 | 30.83 | 44.95 | 50.62 | 58.46 |
|
Market Cap (₹ Cr)
|
7,135.27 | 18,108.89 | 19,071.62 | 20,944.75 | 12,753.19 |
Solvency Ratios
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.55 | 0.28 | 0.02 | 0.13 |
|
Short term debt to equity ratio
|
0.02 | 0.09 | 0.09 | 0.00 | 0.05 |
|
Current Ratio
|
3.02 | 1.41 | 1.55 | 3.99 | 1.83 |
|
Quick Ratio
|
2.31 | 0.77 | 1.00 | 2.89 | 1.00 |
|
Interest Coverage
|
6.25 | 0.89 | 3.04 | 143.52 | 11.20 |
Operating Efficiency Ratios
| Akums Drugs And Pharmaceuticals | Piramal Pharma | Wockhardt | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.81 | 23.05 | 16.85 | 22.50 | 27.51 |
|
Asset Turnover
|
0.88 | 0.56 | 0.43 | 0.81 | 0.92 |
|
Receivable days
|
65.60 | 78.20 | 58.75 | 88.98 | 40.13 |
|
Inventory Days
|
60.15 | 93.30 | 75.82 | 56.04 | 60.29 |
|
Payable days
|
90.39 | 226.14 | 186.21 | 99.95 | 232.47 |
|
Cash Conversion Cycle
|
35.36 | -54.64 | -51.64 | 45.07 | -132.04 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
